HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Integrative medicine for oncology requires ‘educated, evidence-based approach’
-
- Should hem/oncs recommend integrative therapies to their patients?
- Conflict management and data integrity in the shadows John Sweetenham, MD, FRCP, FACP
- Neoadjuvant therapy provides opportunity to discover new treatment strategies Douglas Yee, MD
- Moving forward: HPV vaccination is only the beginning
- New biomarkers and therapeutic target discoveries in molecular oncology Wafik S. El-Deiry, MD, PhD, FACP
- Community health worker intervention may benefit adolescents with sickle cell disease
- Women, older patients with sarcoma more likely to use complementary medicine
- Drug vial optimization reduces waste, saves costs
-
- Oncology pharmacy navigators guide patients to reduce costs, improve treatment compliance
- Tools aid in detection, treatment of cancer-related cognitive impairment
- Pembrolizumab plus chemotherapy prolongs OS, PFS for metastatic lung cancer
- Atezolizumab plus chemotherapy improves small cell lung cancer survival
- LOXO-292 induces durable benefit in RET-altered thyroid cancer
- BLU-667 active in RET-altered thyroid cancer
- Journalist, breast cancer survivor Joan Lunden to speak at Hematology/Oncology Pharmacy Association conference
- Thyroid cancer registry helps predict tumor persistence, recurrence in urban populations
-
- Pathologist pioneered program that allows patients to see ‘the dragon’ they are trying to ‘slay’
- ACCC presents Otis W. Brawley, MD, its prestigious Achievement Award
- Partnership aims to bring early-phase trials to more patients
- Multistrain probiotic may reduce mild, moderate chemotherapy-induced diarrhea
- ESMO honors several oncology leaders
- Post-hoc analysis supports pembrolizumab’s benefit in recurrent head, neck squamous cell carcinoma
- Biden Community Cancer Summit unites physicians, advocates fighting for ‘urgency of now’
- Ruxolitinib-azacytidine combination shows ‘synergistic efficacy’ for myelofibrosis
-
- Lenalidomide ‘best maintenance option’ for multiple myeloma
- 4L lymph node dissection may improve lung cancer survival
- Men whose brothers have aggressive prostate cancer at increased risk
- Rare Hodgkin lymphoma subtype has good prognosis after relapse
- Weight-adjusted tinzaparin provides safe thromboprophylaxis after bariatric surgery
- FDA approves once-weekly Kyprolis for relapsed, refractory multiple myeloma
- FDA awards $18 million to fund trials of medical products for rare diseases
- FDA grants breakthrough therapy designation to Rubraca for prostate cancer
-
- FDA approves Vizimpro for EGFR-mutated non-small cell lung cancer
- Three community oncology practices join forces to ‘transform’ cancer care delivery
- Association of Pediatric Hematology/Oncology Nurses presents several awards
- Lung cancer specialist joins Perlmutter Cancer Center
- CAR T-cell therapy appears safe for multiple myeloma
- Adcetris improves PFS in CD30-expressing peripheral T-cell lymphoma